10 September 2019 ORYZON presents new positive efficacy data on vafidemstat for treatment of aggression
30 July 2019 ORYZON Reports Financial Results and Corporate Update for the First Half Ended June 30, 2019
29 July 2019 ORYZON Announces End of Patient Recruitment for its Phase IIa trials in aggression with vafidemstat: REIMAGINE and REIMAGINE-AD
16 July 2019 ORYZON presents data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles
14-18 July 2019 2019 Alzheimer's Association International Conference (AAIC-2019) Los Angeles Convention Center CA United States